A relativity concept in mesenchymal stromal cell manufacturing

Cytotherapy

Volumn 18, Issue 5, 2016, Pages 613-620

  Martin, Ivan ^a   De Boer, Jan ^b   Sensebe, Luc ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Cellular therapy; Clinical trial; Manufacturing; MSCs

Indexed keywords

CELL AGING; CELL DIFFERENTIATION; CELL EXPANSION; CELL GROWTH; CELL MANUFACTURING; CELL STRUCTURE; CLINICAL EFFECTIVENESS; CLONOGENESIS; CULTURE MEDIUM; CULTURE TECHNIQUE; EXTRACELLULAR MATRIX; GENOMIC INSTABILITY; HUMAN; MESENCHYMAL STROMA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROCESS CONTROL; REVIEW; STANDARDIZATION; TREATMENT INDICATION; BIOLOGICAL THERAPY; CELL CULTURE TECHNIQUE; CYTOLOGY; FEMALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PHYSIOLOGY; PROCEDURES;

CELL AGING; CELL CULTURE TECHNIQUES; CELL- AND TISSUE-BASED THERAPY; FEMALE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED;

EID: 84962092232     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.02.004     Document Type: Review

References (62)

1. Martin I., Ireland H., Baldomero H., Passweg J. The survey on cellular and engineered tissue therapies in Europe in 2012. Tissue Eng Part A 2015, 21:1-13.
2. Bianco P., Cao X., Frenette P.S., Mao J.J., Robey P.G., Simmons P.J., et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med 2013, 19:35-42.
3. Estrada J.C., Torres Y., Benguria A., Dopazo A., Roche E., Carrera-Quintanar L., et al. Human mesenchymal stem cell-replicative senescence and oxidative stress are closely linked to aneuploidy. Cell Death Dis 2013, 4:e691. 10.1038/cddis.2013.211.
4. Siddappa R., Licht R., van Blitterswijk C., de Boer J. Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J Orthop Res 2007, 25:1029-1041.
5. Wagner W., Ho A.D., Zenke M. Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Rev 2010, 16:445-453.
6. Alves H., Munoz-Najar U., De Wit J., Renard A.J., Hoeijmakers J.H., Sedivy J.M., et al. A link between the accumulation of DNA damage and loss of multi-potency of human mesenchymal stromal cells. J Cell Mol Med 2010, 14:2729-2738.
7. Wagner W., Horn P., Castoldi M., Diehlmann A., Bork S., Saffrich R., et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE 2008, 3:e2213.
8. Dominici M., Le B.K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
9. Mentink A., Hulsman M., Groen N., Licht R., Dechering K.J., van der Stok J., et al. Predicting the therapeutic efficacy of MSC in bone tissue engineering using the molecular marker CADM1. Biomaterials 2013, 34:4592-4601.
10. Gronthos S., Zannettino A.C., Hay S.J., Shi S., Graves S.E., Kortesidis A., et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003, 116:1827-1835.
11. Banfi A., Bianchi G., Notaro R., Luzzatto L., Cancedda R., Quarto R. Replicative aging and gene expression in long-term cultures of human bone marrow stromal cells. Tissue Eng 2002, 8:901-910.
12. Bourgine P., Le M.C., Pigeot S., Geurts J., Scherberich A., Martin I. Combination of immortalization and inducible death strategies to generate a human mesenchymal stromal cell line with controlled survival. Stem Cell Res 2014, 12:584-598.
13. Doorn J., Fernandes H.A., Le B.Q., van de Peppel J., van Leeuwen J.P., De Vries M.R., et al. A small molecule approach to engineering vascularized tissue. Biomaterials 2013, 34:3053-3063.
14. Shi S., Gronthos S., Chen S., Reddi A., Counter C.M., Robey P.G., et al. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat Biotechnol 2002, 20:587-591.
15. Simonsen J.L., Rosada C., Serakinci N., Justesen J., Stenderup K., Rattan S.I., et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002, 20:592-596.
16. Redaelli S., Bentivegna A., Foudah D., Miloso M., Redondo J., Riva G., et al. From cytogenomic to epigenomic profiles: monitoring the biologic behavior of in vitro cultured human bone marrow mesenchymal stem cells. Stem Cell Res Ther 2012, 3:47.
17. Izadpanah R., Kaushal D., Kriedt C., Tsien F., Patel B., Dufour J., et al. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res 2008, 68:4229-4238.
18. Sensebe L., Tarte K., Galipeau J., Krampera M., Martin I., Phinney D.G., et al. Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell 2012, 10:9-10.
19. Tarte K., Gaillard J., Lataillade J.J., Fouillard L., Becker M., Mossafa H., et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010, 115:1549-1553.
20. Torsvik A., Rosland G.V., Svendsen A., Molven A., Immervoll H., McCormack E., et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track [letter]. Cancer Res 2010, 70:6393-6396.
21. Fekete N., Rojewski M.T., Lotfi R., Schrezenmeier H. Essential components for ex vivo proliferation of mesenchymal stromal cells. Tissue Eng Part C Methods 2014, 20:129-139.
22. Siddappa R., Fernandes H., Liu J., Van Blitterswijk C., de Boer J. The response of human mesenchymal stem cells to osteogenic signals and its impact on bone tissue engineering. Curr Stem Cell Res Ther 2007, 2:209-220.
23. Stute N., Holtz K., Bubenheim M., Lange C., Blake F., Zander A.R. Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use. Exp Hematol 2004, 32:1212-1225.
24. Meijer G.J., de Bruijn J.D., Koole R., van Blitterswijk C.A. Cell-based bone tissue engineering. PLoS Med 2007, 4:e9.
25. Ulivi V., Tasso R., Cancedda R., Descalzi F. Mesenchymal stem cell paracrine activity is modulated by platelet lysate: induction of an inflammatory response and secretion of factors maintaining macrophages in a proinflammatory phenotype. Stem Cells Dev 2014, 23:1858-1869.
26. Horn P., Bokermann G., Cholewa D., Bork S., Walenda T., Koch C., et al. Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells. Cytotherapy 2010, 12:888-898.
27. Gottipamula S., Muttigi M.S., Kolkundkar U., Seetharam R.N. Serum-free media for the production of human mesenchymal stromal cells: a review. Cell Prolif 2013, 46:608-627.
28. Miwa H., Hashimoto Y., Tensho K., Wakitani S., Takagi M. Xeno-free proliferation of human bone marrow mesenchymal stem cells. Cytotechnology 2012, 64:301-308.
29. Martin I., Muraglia A., Campanile G., Cancedda R., Quarto R. Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow. Endocrinology 1997, 138:4456-4462.
30. Bocelli-Tyndall C., Zajac P., Di M.N., Trella E., Benvenuto F., Iezzi G., et al. Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum 2010, 62:3815-3825.
31. Adesida A.B., Mulet-Sierra A., Jomha N.M. Hypoxia mediated isolation and expansion enhances the chondrogenic capacity of bone marrow mesenchymal stromal cells. Stem Cell Res Ther 2012, 3:9.
32. Basciano L., Nemos C., Foliguet B., de Isla N., de Carvalho M., Tran N., et al. Long term culture of mesenchymal stem cells in hypoxia promotes a genetic program maintaining their undifferentiated and multipotent status. BMC Cell Biol 2011, 12:12.
33. Fehrer C., Brunauer R., Laschober G., Unterluggauer H., Reitinger S., Kloss F., et al. Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell 2007, 6:745-757.
34. Mauney J.R., Kirker-Head C., Abrahamson L., Gronowicz G., Volloch V., Kaplan D.L. Matrix-mediated retention of in vitro osteogenic differentiation potential and in vivo bone-forming capacity by human adult bone marrow-derived mesenchymal stem cells during ex vivo expansion. J Biomed Mater Res A 2006, 79:464-475.
35. Lai Y., Sun Y., Skinner C.M., Son E.L., Lu Z., Tuan R.S., et al. Reconstitution of marrow-derived extracellular matrix ex vivo: a robust culture system for expanding large-scale highly functional human mesenchymal stem cells. Stem Cells Dev 2010, 19:1095-1107.
36. Benoit D.S., Schwartz M.P., Durney A.R., Anseth K.S. Small functional groups for controlled differentiation of hydrogel-encapsulated human mesenchymal stem cells. Nat Mater 2008, 7:816-823.
37. Engler A.J., Sen S., Sweeney H.L., Discher D.E. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126:677-689.
38. Kilian K.A., Bugarija B., Lahn B.T., Mrksich M. Geometric cues for directing the differentiation of mesenchymal stem cells. Proc Natl Acad Sci U S A 2010, 107:4872-4877.
39. McMurray R.J., Gadegaard N., Tsimbouri P.M., Burgess K.V., McNamara L.E., Tare R., et al. Nanoscale surfaces for the long-term maintenance of mesenchymal stem cell phenotype and multipotency. Nat Mater 2011, 10:637-644.
40. Unadkat H.V., Hulsman M., Cornelissen K., Papenburg B.J., Truckenmuller R.K., Carpenter A.E., et al. An algorithm-based topographical biomaterials library to instruct cell fate. Proc Natl Acad Sci U S A 2011, 108:16565-16570.
41. Frith J.E., Thomson B., Genever P.G. Dynamic three-dimensional culture methods enhance mesenchymal stem cell properties and increase therapeutic potential. Tissue Eng Part C Methods 2010, 16:735-749.
42. Eibes G., dos Santos F., Andrade P.Z., Boura J.S., Abecasis M.M., da Silva C.L., et al. Maximizing the ex vivo expansion of human mesenchymal stem cells using a microcarrier-based stirred culture system. J Biotechnol 2010, 146:194-197.
43. Baksh D., Davies J.E., Zandstra P.W. Adult human bone marrow-derived mesenchymal progenitor cells are capable of adhesion-independent survival and expansion. Exp Hematol 2003, 31:723-732.
44. Di M.N., Mehrkens A., Papadimitropoulos A., Schaeren S., Heberer M., Banfi A., et al. Fibroblast growth factor-2 maintains a niche-dependent population of self-renewing highly potent non-adherent mesenchymal progenitors through FGFR2c. Stem Cells 2012, 30:1455-1464.
45. Braccini A., Wendt D., Jaquiery C., Jakob M., Heberer M., Kenins L., et al. Three-dimensional perfusion culture of human bone marrow cells and generation of osteoinductive grafts. Stem Cells 2005, 23:1066-1072.
46. Chatterjea A., Renard A.J., Jolink C., van Blitterswijk C.A., de Boer J. Streamlining the generation of an osteogenic graft by 3D culture of unprocessed bone marrow on ceramic scaffolds. J Tissue Eng Regen Med 2012, 6:103-112.
47. Papadimitropoulos A., Piccinini E., Brachat S., Braccini A., Wendt D., Barbero A., et al. Expansion of human mesenchymal stromal cells from fresh bone marrow in a 3D scaffold-based system under direct perfusion. PLoS ONE 2014, 9:e102359.
48. Di M.N., Piccinini E., Jaworski M., Trumpp A., Wendt D.J., Martin I. Toward modeling the bone marrow niche using scaffold-based 3D culture systems. Biomaterials 2011, 32:321-329.
49. Scherberich A., Galli R., Jaquiery C., Farhadi J., Martin I. Three-dimensional perfusion culture of human adipose tissue-derived endothelial and osteoblastic progenitors generates osteogenic constructs with intrinsic vascularization capacity. Stem Cells 2007, 25:1823-1829.
50. Guven S., Mehrkens A., Saxer F., Schaefer D.J., Martinetti R., Martin I., et al. Engineering of large osteogenic grafts with rapid engraftment capacity using mesenchymal and endothelial progenitors from human adipose tissue. Biomaterials 2011, 32:5801-5809.
51. Krampera M., Galipeau J., Shi Y., Tarte K., Sensebe L. Immunological characterization of multipotent mesenchymal stromal cells-the International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013, 15:1054-1061.
52. Wuchter P., Bieback K., Schrezenmeier H., Bornhauser M., Muller L.P., Bonig H., et al. Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy 2015, 17:128-139.
53. Galipeau J., Krampera M. The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. Cytotherapy 2015, 17:125-127.
54. Galipeau J., Krampera M., Barrett J., Dazzi F., Deans R.J., DeBruijn J., et al. International society for cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 2015, 18:151-159.
55. Rama P., Matuska S., Paganoni G., Spinelli A., De L.M., Pellegrini G. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 2010, 363:147-155.
56. Francois M., Copland I.B., Yuan S., Romieu-Mourez R., Waller E.K., Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 2012, 14:147-152.
57. Martin I., Simmons P.J., Williams D.F. Manufacturing challenges in regenerative medicine. Sci Transl Med 2014, 6:232fs16.
58. Hourd P., Ginty P., Chandra A., Williams D.J. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability. Cytotherapy 2014, 16:1033-1047.
59. Viswanathan S., Keating A., Deans R., Hematti P., Prockop D., Stroncek D.F., et al. Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells Dev 2014, 23:1157-1167.
60. Tanavde V., Vaz C., Rao M.S., Vemuri M.C., Pochampally R.R. Research using Mesenchymal Stem/Stromal Cells: quality metric towards developing a reference material. Cytotherapy 2015, 17:1169-1177.
61. Deans R. Towards the creation of a standard MSC line as a calibration tool. Cytotherapy 2015, 17:1167-1168.
62. Olson S.D., Pollock K., Kambal A., Cary W., Mitchell G.M., Tempkin J., et al. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Mol Neurobiol 2012, 45:87-98.